Agendia

Agendia provides molecular diagnostics and personalized treatment plans for cancer patients.

Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. MammaPrintÂ, Agendiaâ€s main product for breast cancer, analyzes tumors based on a 70 gene signature and offers innovative, unbiased and clinically significant insight into tumor biology. It is the first FDA cleared breast cancer gene profiling assay of its kind and provides a highly accurate determination of metastasis risk (low or high) and distant recurrence within 10 years.